Biodel reports new findings from key programs for its diabetes drug candidate Linjeta

15 November 2010

Scientists from USA-based specialty pharmaceutical firm Biodel (Nasdaq: BIOD) reported new findings from the company's Linjeta, (insulin glargine), "smart" basal insulin and stabilized glucagon development programs in poster presentations at the Tenth Annual Diabetes Technology Meeting in Bethesda, Maryland, USA, last Friday.

The US Food and Drug Administration recently issued a Complete Response Letter requesting additional late-stage information regarding Biodel’s New Drug Application for Linjeta for the treatment of type 1 and type 2 diabetes mellitus to improve glycemic control, news that caused the company’s share price slump 52% on that day (The Pharma Letter November 2).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

More ones to watch >